Table 2A.
The association of key clinical disease features with autoantibody subgroups.
| Classified as PM (%) | Dysphagiaa (%) | Calcinosisa (%) | Ulcerationa (%) | Oedemaa (%) | Lipoatrophya (%) | Arthritisa (%) | |
|---|---|---|---|---|---|---|---|
| Total cohort (n = 379)b | 10 (2.6) | 96 (26) | 120 (32) | 76 (20) | 155 (41) | 57 (15) | 148 (40) |
| Anti-TIF1γ (n = 68) |
0 | 18 (26) | 25 (37) | 23 (34)*** | 32 (47) | 13 (19) | 26 (38) |
| Anti-NXP2 (n = 59) |
0 | 17 (29) | 25 (43) | 8 (14) | 26 (44) | 9 (16) | 20 (34) |
| Anti-MDA5 (n = 23) |
0 | 7 (30) | 7 (27) | 11 (50)*** | 10 (43) | 3 (13) | 15 (65)* |
| Anti-PmScl (n = 20) |
0 | 5 (25) | 11 (55)* | 4 (20) | 5 (25) | 6 (30)* | 11 (44) |
| Anti- Mi2 (n = 15) |
0 | 7 (47)* | 4 (27) | 0 | 11 (73)* | 2 (13) | 6 (40) |
| Anti-U1RNP (n = 14) |
3 (21)*** | 6 (43) | 1 (8) | 2 (14) | 2 (14) | 2 (14) | 7 (50) |
| Anti-SRP (n = 7) |
2 (29)*** | 3 (43) | 1 (14) | 4 (50)** | 5 (71) | 1 (13) | 2 (29) |
| Anti-synthetasec (n = 6) |
0 | 0 | 1 (17) | 2 (33) | 3 (50) | 2 (33)* | 2 (33) |
| Anti-HMGCR (n = 4) |
2 (50)*** | 3 (75)* | 0 | 0 | 0 | 0 | 0 |
| Anti-SAE (n = 3) |
0 | 0 | 1 (33) | 1 (33) | 1 (33) | 1 (33) | 2 (66) |
| Otherd (n = 5) |
1 (20)** | 3 (60) | 1 (20) | 2 (50) | 1 (20) | 2 (50) | 3 (60) |
| Nil identifiede (n = 155) |
2 (1) | 27 (17) | 44 (28) | 19 (12) | 59 (38) | 16 (10) | 54 (35) |
Statistically significant associations are highlighted in bold.
*P < 0.05, **P < 0.01, ***P < 0.001, PM; polymyositis.
a
Data available for 374 patients.
b
Including 8 patients with other idiopathic inflammatory myopathy.
c
3 patients anti-Jo-1, 2 patients anti-PL12 and 1 patient anti-PL7.
d
1 anti-Ku, 1 anti-Scl70, 1 anti-Ro60, 1 anti-U3RNP, 1 anti-mitochondrial antibody.
e
No known autoantibody identified using the techniques described (42% of this group have unidentified bands visible on immunoprecipitation).